- No Data
English
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, the research team of the Special Glass and Fiber Research Center of the Advanced Laser and Optoelectronic Functional Materials Department of the Shanghai Institute of Optics and Fine Mechanics, Chinese Academy of Sciences, aimed at the demand for in-situ detection of Raman signals, expanded the functions of the laboratory commercial Renishaw Invia confocal micro Raman spectrometer by usi...
Through joint research, a team developed a 4-amino-TEMPO derivative with photocatalytic performance and successfully used it to produce high-performance and stable fiber like dye sensitized solar cells (FDSSCs) and fiber like organic light-emitting diodes (FOLEDs). This paper was published in the journal Materials and Energy Today.The developed 4-amino-TEMPO derivatives have the characteristic of ...
Scientists from the Stanford National Accelerator (SLAC) laboratory of the US Department of Energy have revealed new information about the photoelectric effect using attosecond pulses: the delay time of photoelectric emission is as long as 700 attosecond, far exceeding previous expectations. The latest research challenges existing theoretical models and helps to reveal the interactions between ele...
IntroductionVortex beams carrying orbital angular momentum (OAM) are widely used for high-throughput optical information multiplexing, and achieving on chip, small-scale vortex lasers is crucial for promoting the industrial implementation of vortex light reuse technology. Recently, Gu Min, an academician of Shanghai University of Technology, and Fang Xinyuan, an associate professor of Shanghai Uni...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...